Oral Topotecan With Toripalimab for Patients With Endometrial Cancer

Phase 2
Not yet recruiting
Conditions
Interventions
Registration Number
NCT06548763
Lead Sponsor
Fudan University
Brief Summary

This study aims to explore the safety and efficacy of oral topotecan combined with toripalimab in treating advanced/recurrent endometrial cancer through a single-center, prospective, single-arm, phase II clinical trial. The goal is to explore the first-line treatment options for endometrial cancer patients in the era of immunotherapy, to improve the overall ...

Detailed Description

1. Overall Design This trial is a single-center, prospective, single-arm, phase II clinical trial to evaluate the safety and efficacy of oral topotecan combined with toripalimab in treating advanced/recurrent endometrial cancer.
...

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
30
Inclusion Criteria
  1. Age ≥ 18 years old, female;
  2. Patients with advanced/recurrent endometrial cancer diagnosed by histopathology and failed first-line treatment;
  3. Can provide 10 pathological white films for subsequent research;
  4. Physical fitness status score ECOG ≤ 2;
  5. Expected survival period ≥ 3 months;
  6. The subjects can understand the research process, voluntarily participate in this study, sign informed consent forms, have good compliance, and cooperate with follow-up.
Read More
Exclusion Criteria
  1. Pregnant and lactating patients, women of childbearing age who refuse to take effective contraceptive measures during the study period; Individuals with peripheral nervous system disorders caused by diseases or those with a history of significant mental and central nervous system disorders;
  2. Serious or uncontrolled infections that may affect research treatment or evaluation of research results, including but not limited to active hepatitis virus infections, positive human immunodeficiency virus (HIV) antibodies, lung infections, etc;
  3. Individuals who are known to be allergic, highly sensitive, or intolerant to the active ingredients or other components of the investigational drug;
  4. Other malignant tumors have appeared within the past 5 years, except for cured cervical carcinoma in situ and non melanoma skin cancer;
  5. Patients who are currently participating or have participated in other clinical trials within the past month;
  6. The researchers determined that the patients were not suitable to participate in this study.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Topotecanwith TerriptylimabToripalimabOral administration of topotecan and intravenous infusion of trastuzumab until disease progression or toxicity intolerance occurs.
Topotecanwith TerriptylimabTopotecanOral administration of topotecan and intravenous infusion of trastuzumab until disease progression or toxicity intolerance occurs.
Primary Outcome Measures
NameTimeMethod
PFSTwo years

Progression free survival

Secondary Outcome Measures
NameTimeMethod
OSTwo years

Overall Survival

ORRTwo years

Overall Remission Rate

Trial Locations

Locations (1)

Fudan university shanghai cancer center, Deparment of gynecologic oncology

🇨🇳

Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath